secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2026-04-01T23:59:59+00:00
Accession:  0001193125-26-135669
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome acquires global rights to PDE10A inhibitor balipodect from Takeda
------------------------------------------------------------------------

- Obtained exclusive worldwide rights to balipodect, a selective PDE10A inhibitor, from Takeda.
- Balipodect completed a 164-patient Phase 2 trial in schizophrenia; safety profile established in over 360 individuals.
- Axsome plans to start Phase 3-enabling activities for schizophrenia in 2026 and also target Tourette syndrome.
- Takeda received an upfront payment and is eligible for development, regulatory, and commercial milestones plus royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000119312526135669/0001193125-26-135669-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000119312526135669/axsm-20260401.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-135669

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer